HuGE Literature Finder
|
||
Records 1-34
|
Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
Medical oncology (Northwood, London, England) 2018 Aug 35 (9): 119. Helbig Grzego |
|
Prevalence of CALR mutations in splanchnic vein thrombosis: A systematic review and meta-analysis.
Thrombosis research 2018 May 167 96-103. Li Miaomiao, De Stefano Valerio, Song Tingxue, Zhou Xinmiao, Guo Zeqi, Zhu Jia, Qi Xingsh |
|
Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study.
Journal of hepatology 2017 May . Poisson Johanne, Plessier Aurélie, Kiladjian Jean-Jacques, Turon Fanny, Cassinat Bruno, Andreoli Annalisa, De Raucourt Emmanuelle, Goria Odile, Zekrini Kamal, Bureau Christophe, Lorre Florence, Cervantes Francisco, Colomer Dolors, Durand François, Garcia-Pagan Juan-Carlos, Casadevall Nicole, Valla Dominique-Charles, Rautou Pierre-Emmanuel, Marzac Christophe, |
|
[Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance].
Zhongguo shi yan xue ye xue za zhi 2017 Feb 25 (1): 151-156. Tang Qin, Zhang Xiu-Wen, Xia Lei, Jiang Nai- |
|
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.
Journal of hematology & oncology 2017 Feb 10 (1): 54. Lussana Federico, Carobbio Alessandra, Salmoiraghi Silvia, Guglielmelli Paola, Vannucchi Alessandro Maria, Bottazzi Barbara, Leone Roberto, Mantovani Alberto, Barbui Tiziano, Rambaldi Alessand |
|
Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2(V617F) mutations and laboratory findings: a meta-analysis.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2017 Feb . Saki N, Shirzad R, Rahim F, Saki Malehi |
|
[Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease].
Terapevticheskii arkhiv 2017 89 (7): 4-9. Melikyan A L, Subortseva I N, Sudarikov A B, Kovrigina A M, Gilyazitdinova E A, Kolosheinova T I, Abdullaev A O, Treglazova S |
|
Re: Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis.
Annals of hematology 2016 Sep . Kourie Hampig Raphael, Ameye Lieveke, Paesmans Marianne, Bron Dominiq |
|
Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
Oncotarget 2016 Jul . Min-Gu Kang, Hyun-Woo Choi, Jun Hyung Lee, Yong Jun Choi, Hyun-Jung Choi, Jong-Hee Shin, Soon-Pal Suh, Szardenings Michael, Hye-Ran Kim, Myung-Geun Sh |
|
Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis.
Annals of hematology 2016 Jul . Pei Yu-Qing, Wu Yue, Wang Fei, Cui W |
|
Thrombotic risk correlates with mutational status in true-essential thrombocythemia.
European journal of clinical investigation 2016 Jun . Bertozzi I, Peroni E, Coltro G, Bogoni G, Cosi E, Santarossa C, Fabris F, Randi M |
|
Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
American journal of hematology 2016 May 91 (5): 503-6. Elala Yoseph C, Lasho Terra L, Gangat Naseema, Finke Christy, Barraco Daniela, Haider Mahnur, Abou Hussein Ahmed K, Hanson Curtis A, Ketterling Rhett P, Pardanani Animesh, Tefferi Ayal |
|
Molecular biomarkers of thrombosis in myeloproliferative neoplasms.
Thrombosis research 2016 Apr 140 Suppl 1 S71-5. Barbui Tiziano, Falanga An |
|
PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status.
Thrombosis research 2016 Apr 140 Suppl 1 S183. Vignoli A, Tessarolo S, Marchetti M, Gamba S, Piras F, Finazzi G, van der Meijden P E J, Swieringa F, Ten Cate H, Heemskerk J W M, Rambaldi A, Falanga |
|
Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
Clinical lymphoma, myeloma & leukemia 2016 Feb . Kourie Hampig Raphael, Ameye Lieveke, Paesmans Marianne, Bron Dominiq |
|
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.
Leukemia 2015 Oct . Pietra D, Rumi E, Ferretti V V, Di Buduo C A, Milanesi C, Cavalloni C, Sant'Antonio E, Abbonante V, Moccia F, Casetti I C, Bellini M, Renna M C, Roncoroni E, Fugazza E, Astori C, Boveri E, Rosti V, Barosi G, Balduini A, Cazzola |
|
Genetic Risk Factors of Venous Thromboembolism in the East Algerian Population.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2015 Aug . Moussaoui S, Saussoy P, Ambroise J, Defour J P, Zouitene R, Sifi K, Abadi |
|
JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis.
Pathology oncology research : POR 2015 Jul 21 (3): 751-8. Pósfai Éva, Marton Imelda, Király Péter Attila, Kotosz Balázs, Kiss-László Zsuzsanna, Széll Márta, Borbényi Zi |
|
Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation.
British journal of haematology 2015 Jun . Torregrosa Jose M, Ferrer-Marín Francisca, Lozano María L, Moreno Maria J, Martinez Constantino, Anton Ana I, Rivera José, Vicente Vicen |
|
Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.
European journal of haematology 2015 Jun . Mela Osorio María J, Ferrari Luciana, Goette Nora P, Gutierrez Marina I, Glembotsky Ana C, Maldonado Ana C, Lev Paola R, Alvarez Clarisa, Korin Laura, Marta Rosana F, Molinas Felisa C, Heller Paula |
|
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.
Leukemia 2015 Jun 29 (6): 1344-9. Palandri F, Latagliata R, Polverelli N, Tieghi A, Crugnola M, Martino B, Perricone M, Breccia M, Ottaviani E, Testoni N, Merli F, Aversa F, Alimena G, Cavo M, Martinelli G, Catani L, Baccarani M, Vianelli |
|
Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.
Leukemia research 2015 May 39 (5): 525-9. Gianelli Umberto, Iurlo Alessandra, Cattaneo Daniele, Bossi Anna, Cortinovis Ivan, Augello Claudia, Moro Alessia, Savi Federica, Castelli Roberto, Brambilla Cecilia, Bianchi Paola, Primignani Massimo, Cortelezzi Agostino, Bosari Silva |
|
[Essential thrombocythemia: baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients].
Medicina clínica 2015 Mar 144 (6): 247-53. Angona Anna, Alvarez-Larrán Alberto, Bellosillo Beatriz, Martínez-Avilés Luz, Garcia-Pallarols Francesc, Longarón Raquel, Ancochea Àgueda, Besses Carl |
|
Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.
Annals of laboratory medicine 2015 Mar 35 (2): 233-7. Park Sang Hyuk, Kim Shine Young, Lee Sun Min, Yi Jongyoun, Kim In-Suk, Kim Hyung Hoi, Chang Chulhun Ludgerus, Lee Eun Yup, Song Moo-Kon, Shin Ho-Jin, Chung Joo Se |
|
A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.
International journal of hematology 2015 Feb 101 (2): 165-72. Yang Yining, Wang Xiaorui, Wang Chun, Qin Youw |
|
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
European journal of haematology 2015 Jan 94 (1): 31-6. Gangat Naseema, Wassie Emnet A, Lasho Terra L, Finke Christy, Ketterling Rhett P, Hanson Curtis A, Pardanani Animesh, Wolanskyj Alexandra P, Maffioli Margherita, Casalone Rosario, Passamonti Francesco, Tefferi Ayal |
|
Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis.
Journal of hepatology 2015 Jan 62 (1): 72-4. Turon Fanny, Cervantes Francisco, Colomer Dolors, Baiges Anna, Hernández-Gea Virginia, Garcia-Pagán Juan Carl |
|
Calreticulin mutations and long-term survival in essential thrombocythemia.
Leukemia 2014 Dec 28 (12): 2300-3. Tefferi A, Wassie E A, Lasho T L, Finke C, Belachew A A, Ketterling R P, Hanson C A, Pardanani A, Gangat N, Wolanskyj A |
|
Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.
Annals of hematology 2014 Dec 93 (12): 2029-36. Chen Chih-Cheng, Gau Jyh-Pyng, Chou Hui-Ju, You Jie-Yu, Huang Cih-En, Chen Yi-Yang, Lung Jrhau, Chou Yi-Sheng, Leu Yu-Wei, Lu Chang-Hsien, Lee Kuan-Der, Tsai Ying-Hua |
|
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
Blood 2014 Aug 124 (7): 1062-9. Rumi Elisa, Pietra Daniela, Pascutto Cristiana, Guglielmelli Paola, Martínez-Trillos Alejandra, Casetti Ilaria, Colomer Dolors, Pieri Lisa, Pratcorona Marta, Rotunno Giada, Sant'Antonio Emanuela, Bellini Marta, Cavalloni Chiara, Mannarelli Carmela, Milanesi Chiara, Boveri Emanuela, Ferretti Virginia, Astori Cesare, Rosti Vittorio, Cervantes Francisco, Barosi Giovanni, Vannucchi Alessandro M, Cazzola Mario, |
|
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.
Blood 2014 Apr 123 (15): 2416-9. Rumi Elisa, Harutyunyan Ashot S, Pietra Daniela, Milosevic Jelena D, Casetti Ilaria C, Bellini Marta, Them Nicole C C, Cavalloni Chiara, Ferretti Virginia V, Milanesi Chiara, Berg Tiina, Sant'Antonio Emanuela, Boveri Emanuela, Pascutto Cristiana, Astori Cesare, Kralovics Robert, Cazzola Mario, |
|
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.
Blood 2014 Mar 123 (10): 1552-5. Rotunno Giada, Mannarelli Carmela, Guglielmelli Paola, Pacilli Annalisa, Pancrazzi Alessandro, Pieri Lisa, Fanelli Tiziana, Bosi Alberto, Vannucchi Alessandro M, |
|
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Blood 2014 Mar 123 (10): 1544-51. Rumi Elisa, Pietra Daniela, Ferretti Virginia, Klampfl Thorsten, Harutyunyan Ashot S, Milosevic Jelena D, Them Nicole C C, Berg Tiina, Elena Chiara, Casetti Ilaria C, Milanesi Chiara, Sant'antonio Emanuela, Bellini Marta, Fugazza Elena, Renna Maria C, Boveri Emanuela, Astori Cesare, Pascutto Cristiana, Kralovics Robert, Cazzola Mario, |
|
Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.
Chinese medical journal 0 129 (15): 1778-1783. Sun Chao, Zhou Xin, Zou Zhi-Jian, Guo Hong-Feng, Li Jian-Yong, Qiao Ch |
- Page last reviewed:Jul 30, 2019
- Page last updated:Aug 15, 2019
- Content source: